Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Figure 3

Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer receiving trastuzumab–taxane. Differences between the survival times (days) for patients whose HER2/neu concentrations at 2 to 2 weeks of treatment had fallen to ≤ 77% of baseline values and those whose values had remained at >77% of baseline values (respective survival times 587 and 119 days).

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us